Walleye Capital LLC Sells 137,200 Shares of Immatics (NASDAQ:IMTX)

Walleye Capital LLC lowered its position in Immatics (NASDAQ:IMTX) by 32.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 282,193 shares of the company’s stock after selling 137,200 shares during the period. Walleye Capital LLC’s holdings in Immatics were worth $3,220,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IMTX. AlphaCentric Advisors LLC increased its stake in Immatics by 14.3% during the 2nd quarter. AlphaCentric Advisors LLC now owns 20,000 shares of the company’s stock worth $232,000 after purchasing an additional 2,500 shares in the last quarter. TD Asset Management Inc increased its position in shares of Immatics by 11.8% during the second quarter. TD Asset Management Inc now owns 357,526 shares of the company’s stock worth $4,154,000 after acquiring an additional 37,770 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Immatics during the second quarter worth $321,000. HighVista Strategies LLC bought a new stake in Immatics in the 2nd quarter valued at $904,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Immatics in the 2nd quarter worth $2,404,000. 64.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Piper Sandler assumed coverage on Immatics in a research note on Monday, October 7th. They issued an “overweight” rating and a $19.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th. The Goldman Sachs Group raised shares of Immatics to a “strong-buy” rating in a research note on Monday, November 25th. Finally, Bank of America cut their price objective on shares of Immatics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $16.67.

Immatics Stock Performance

Shares of NASDAQ IMTX opened at $8.32 on Tuesday. The stock has a 50 day moving average price of $9.47 and a 200 day moving average price of $11.05. The stock has a market capitalization of $993.04 million, a PE ratio of -12.61 and a beta of 0.78. Immatics has a 52 week low of $7.46 and a 52 week high of $13.77.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.